Paliperidone
- Generic Name
- Paliperidone
- Brand Names
- Invega, Invega Hafyera, Xeplion, Niapelf, Byannli (previously Paliperidone Janssen-Cilag International), Trevicta (previously Paliperidone Janssen), ERZOFRI
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O3
- CAS Number
- 144598-75-4
- Unique Ingredient Identifier
- 838F01T721
- Background
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperido...
- Indication
As an oral extended-release tablet and a once-monthly extended-release suspension for intramuscular injection, paliperidone is indicated for the treatment of adults and adolescents with schizophrenia and in the treatment of schizoaffective disorder in combination with antidepressants or mood stabilizers. Paliperidone is also available in both an every-three-...
- Associated Conditions
- Schizoaffective Disorders, Schizophrenia
- Associated Therapies
- -
Drug giants display advanced technologies, solutions at CIIE
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.